Viking Long Term Debt Total vs Deferred Long Term Liab Analysis

VKTX Stock

USD 52.59 0.96 1.86%

Viking Therapeutics financial indicator trend analysis is much more than just breaking down Viking Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viking Therapeutics is a good investment. Please check the relationship between Viking Therapeutics Long Term Debt Total and its Deferred Long Term Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Long Term Debt Total vs Deferred Long Term Liab

Long Term Debt Total vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Viking Therapeutics Long Term Debt Total account and Deferred Long Term Liab. At this time, the significance of the direction appears to have very week relationship.

The correlation between Viking Therapeutics' Long Term Debt Total and Deferred Long Term Liab is 0.27. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Viking Therapeutics, assuming nothing else is changed. The correlation between historical values of Viking Therapeutics' Long Term Debt Total and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Viking Therapeutics are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Long Term Debt Total i.e., Viking Therapeutics' Long Term Debt Total and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Long Term Debt Total

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Viking Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viking Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.Selling General Administrative is likely to rise to about 38.9 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (16.03).

Viking Therapeutics fundamental ratios Correlations

	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Other Liab	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Other Assets	Other Current Assets	Deferred Long Term Liab
Short Long Term Debt Total		0.0	0.3	-0.17	0.05	-0.09	0.18	-0.11	0.63	-0.04	0.34	-0.11	-0.14	0.26	0.02	0.31	0.31	-0.14	-0.09	-0.14	0.93	-0.21	-0.18	-0.42	-0.09	-0.45
Other Current Liab	0.0		0.63	0.79	-0.94	-0.97	0.93	0.8	-0.08	0.92	0.6	0.81	0.81	-0.28	0.94	0.38	-0.25	0.8	0.86	0.81	-0.12	0.64	-0.79	-0.69	0.83	-0.65
Total Current Liabilities	0.3	0.63		0.36	-0.56	-0.63	0.74	0.5	0.2	0.5	0.99	0.5	0.4	0.02	0.56	0.91	0.52	0.39	0.55	0.4	0.03	0.3	-0.42	-0.38	0.55	-0.35
Total Stockholder Equity	-0.17	0.79	0.36		-0.87	-0.82	0.67	0.87	-0.26	0.96	0.31	0.88	1.0	-0.36	0.86	0.17	-0.28	1.0	0.87	1.0	-0.23	0.88	-0.83	-0.7	0.62	-0.66
Net Debt	0.05	-0.94	-0.56	-0.87		0.96	-0.87	-0.78	0.14	-0.96	-0.51	-0.79	-0.89	0.35	-1.0	-0.3	0.24	-0.88	-0.83	-0.88	0.15	-0.65	0.74	0.64	-0.64	0.59
Retained Earnings	-0.09	-0.97	-0.63	-0.82	0.96		-0.92	-0.77	0.02	-0.95	-0.59	-0.78	-0.84	0.28	-0.97	-0.39	0.2	-0.84	-0.85	-0.84	0.03	-0.61	0.78	0.72	-0.74	0.67
Accounts Payable	0.18	0.93	0.74	0.67	-0.87	-0.92		0.63	-0.01	0.83	0.72	0.64	0.7	-0.22	0.88	0.58	-0.07	0.69	0.7	0.7	-0.01	0.45	-0.63	-0.57	0.7	-0.53
Common Stock Total Equity	-0.11	0.8	0.5	0.87	-0.78	-0.77	0.63		-0.18	0.85	0.44	1.0	0.87	-0.39	0.74	0.23	-0.26	0.86	0.99	0.87	-0.16	0.93	-0.9	-0.77	0.81	-0.74
Non Current Liabilities Total	0.63	-0.08	0.2	-0.26	0.14	0.02	-0.01	-0.18		-0.15	0.29	-0.18	-0.24	0.64	-0.1	0.19	0.3	-0.24	-0.16	-0.24	0.58	-0.26	-0.03	-0.26	-0.08	-0.23
Other Stockholder Equity	-0.04	0.92	0.5	0.96	-0.96	-0.95	0.83	0.85	-0.15		0.46	0.86	0.97	-0.33	0.96	0.29	-0.25	0.96	0.89	0.97	-0.14	0.78	-0.84	-0.74	0.7	-0.69
Total Liab	0.34	0.6	0.99	0.31	-0.51	-0.59	0.72	0.44	0.29	0.46		0.44	0.36	0.17	0.52	0.92	0.56	0.35	0.49	0.35	0.05	0.25	-0.4	-0.37	0.51	-0.34
Common Stock	-0.11	0.81	0.5	0.88	-0.79	-0.78	0.64	1.0	-0.18	0.86	0.44		0.88	-0.39	0.76	0.23	-0.26	0.87	0.99	0.88	-0.16	0.93	-0.91	-0.78	0.81	-0.74
Total Assets	-0.14	0.81	0.4	1.0	-0.89	-0.84	0.7	0.87	-0.24	0.97	0.36	0.88		-0.34	0.88	0.22	-0.24	1.0	0.88	1.0	-0.22	0.88	-0.84	-0.7	0.63	-0.66
Other Liab	0.26	-0.28	0.02	-0.36	0.35	0.28	-0.22	-0.39	0.64	-0.33	0.17	-0.39	-0.34		-0.33	0.21	0.44	-0.34	-0.39	-0.34	0.2	-0.33	0.19	0.05	-0.28	0.04
Cash	0.02	0.94	0.56	0.86	-1.0	-0.97	0.88	0.74	-0.1	0.96	0.52	0.76	0.88	-0.33		0.32	-0.22	0.87	0.8	0.87	-0.1	0.62	-0.73	-0.65	0.62	-0.61
Non Current Assets Total	0.31	0.38	0.91	0.17	-0.3	-0.39	0.58	0.23	0.19	0.29	0.92	0.23	0.22	0.21	0.32		0.73	0.21	0.27	0.21	-0.02	0.1	-0.17	-0.14	0.31	-0.12
Non Currrent Assets Other	0.31	-0.25	0.52	-0.28	0.24	0.2	-0.07	-0.26	0.3	-0.25	0.56	-0.26	-0.24	0.44	-0.22	0.73		-0.24	-0.26	-0.24	0.08	-0.25	0.26	0.24	-0.25	0.22
Cash And Short Term Investments	-0.14	0.8	0.39	1.0	-0.88	-0.84	0.69	0.86	-0.24	0.96	0.35	0.87	1.0	-0.34	0.87	0.21	-0.24		0.87	1.0	-0.22	0.87	-0.83	-0.7	0.61	-0.66
Common Stock Shares Outstanding	-0.09	0.86	0.55	0.87	-0.83	-0.85	0.7	0.99	-0.16	0.89	0.49	0.99	0.88	-0.39	0.8	0.27	-0.26	0.87		0.87	-0.15	0.88	-0.89	-0.77	0.85	-0.73
Total Current Assets	-0.14	0.81	0.4	1.0	-0.88	-0.84	0.7	0.87	-0.24	0.97	0.35	0.88	1.0	-0.34	0.87	0.21	-0.24	1.0	0.87		-0.22	0.88	-0.84	-0.7	0.63	-0.66
Short Term Debt	0.93	-0.12	0.03	-0.23	0.15	0.03	-0.01	-0.16	0.58	-0.14	0.05	-0.16	-0.22	0.2	-0.1	-0.02	0.08	-0.22	-0.15	-0.22		-0.22	-0.16	-0.41	-0.16	-0.46
Net Tangible Assets	-0.21	0.64	0.3	0.88	-0.65	-0.61	0.45	0.93	-0.26	0.78	0.25	0.93	0.88	-0.33	0.62	0.1	-0.25	0.87	0.88	0.88	-0.22		-0.88	-0.72	0.69	-0.7
Current Deferred Revenue	-0.18	-0.79	-0.42	-0.83	0.74	0.78	-0.63	-0.9	-0.03	-0.84	-0.4	-0.91	-0.84	0.19	-0.73	-0.17	0.26	-0.83	-0.89	-0.84	-0.16	-0.88		0.96	-0.77	0.94
Other Assets	-0.42	-0.69	-0.38	-0.7	0.64	0.72	-0.57	-0.77	-0.26	-0.74	-0.37	-0.78	-0.7	0.05	-0.65	-0.14	0.24	-0.7	-0.77	-0.7	-0.41	-0.72	0.96		-0.65	0.99
Other Current Assets	-0.09	0.83	0.55	0.62	-0.64	-0.74	0.7	0.81	-0.08	0.7	0.51	0.81	0.63	-0.28	0.62	0.31	-0.25	0.61	0.85	0.63	-0.16	0.69	-0.77	-0.65		-0.61
Deferred Long Term Liab	-0.45	-0.65	-0.35	-0.66	0.59	0.67	-0.53	-0.74	-0.23	-0.69	-0.34	-0.74	-0.66	0.04	-0.61	-0.12	0.22	-0.66	-0.73	-0.66	-0.46	-0.7	0.94	0.99	-0.61

Click cells to compare fundamentals

Viking Therapeutics Account Relationship Matchups

Viking Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	4.0M	7.5M	7.3M	12.8M	11.0M	11.5M
Total Current Liabilities	6.8M	12.1M	8.8M	21.9M	19.1M	10.4M
Total Stockholder Equity	277.1M	244.3M	201.9M	145.3M	348.4M	365.8M
Net Debt	(7.7M)	(28.8M)	(26.3M)	(35.1M)	(54.3M)	(51.5M)
Retained Earnings	(128.7M)	(168.2M)	(223.2M)	(292.0M)	(377.9M)	(359.0M)
Accounts Payable	2.4M	4.0M	1.4M	8.5M	7.5M	7.9M
Non Current Liabilities Total	360K	29K	1.5M	1.3M	936K	1.1M
Other Stockholder Equity	405.8M	412.6M	425.6M	438.5M	726.8M	763.1M
Total Liab	7.1M	12.2M	8.8M	23.2M	20.1M	11.3M
Total Assets	284.3M	256.5M	210.7M	168.5M	368.5M	386.9M
Cash	8.4M	29.1M	26.4M	36.6M	55.5M	58.3M
Non Current Assets Total	755K	398K	134K	1.5M	1.3M	755.8K
Non Currrent Assets Other	157K	77K	109K	71K	139K	132.1K
Cash And Short Term Investments	275.6M	248.4M	202.1M	155.5M	362.1M	380.2M
Common Stock Shares Outstanding	72.0M	72.6M	77.2M	76.8M	94.3M	50.8M
Liabilities And Stockholders Equity	284.3M	256.5M	210.7M	168.5M	368.5M	386.9M
Total Current Assets	283.5M	256.1M	210.5M	167.0M	367.2M	385.6M
Net Tangible Assets	277.1M	244.3M	201.9M	145.3M	167.1M	143.6M
Other Assets	157K	398K	109K	71K	63.9K	60.7K
Other Current Assets	7.9M	7.7M	8.4M	11.6M	5.1M	4.9M
Deferred Long Term Liab	128K	48K	76K	38K	34.2K	32.5K
Retained Earnings Total Equity	(128.7M)	(168.2M)	(223.2M)	(292.0M)	(262.8M)	(249.7M)
Short Term Investments	267.3M	219.3M	175.7M	118.9M	306.6M	171.0M
Capital Surpluse	405.8M	412.6M	425.6M	445.3M	512.1M	317.3M
Accumulated Other Comprehensive Income	12K	(54K)	(549K)	(1.1M)	(389K)	(408.5K)
Net Invested Capital	277.1M	244.3M	201.9M	145.3M	348.4M	240.7M
Net Working Capital	276.7M	244.0M	201.8M	145.1M	348.1M	239.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viking Long Term Debt Total vs Deferred Long Term Liab Analysis

Long Term Debt Total vs Deferred Long Term Liab

Long Term Debt Total vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Long Term Debt Total

Deferred Long Term Liab

Viking Therapeutics fundamental ratios Correlations

Viking Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viking Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Viking Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets

Cash	- 1.0	Net Debt
Cash	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Other Stockholder Equity	- 0.96	Net Debt
Other Stockholder Equity	- 0.95	Retained Earnings
Net Debt	- 0.94	Other Current Liab